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The Small Antitumoral Immune Response Modifier
Imiquimod Interacts with Adenosine Receptor
Signaling in a TLR7- and TLR8-Independent Fashion
Michael P. Scho¨n1,3, Margarete Scho¨n1,3 and Karl-Norbert Klotz2
Imiquimod, a small-molecule immune response modifier of the imidazoquinoline family, has shown profound
antitumoral and antiviral efficacy both in vitro and in clinical applications in vivo. It has been demonstrated that
this activity is mediated through the Toll-like receptor (TLR)7- and TLR8-signaling cascade resulting in the
secretion of proinflammatory cytokines and, consecutively, induction of a tumor-directed cellular immune
response. In addition, imiquimod exerts a direct proapoptotic activity in tumor cells. We demonstrate here that
imiquimod induces activation of the transcription factor NF-kB and the downstream production of
proinflammatory cytokines in the absence of TLR7 and TLR8. In Chinese hamster ovary cells stably transfected
with the human adenosine receptor subtypes, we then show in radioligand-binding competition experiments
that imiquimod binds to adenosine receptors at concentrations relevant in clinical settings, with highest
affinities to the A1 and A2A subtypes. The effect on the receptor-mediated activation of adenylyl cyclase was also
studied, and these experiments revealed that imiquimod acts as an adenosine receptor antagonist. In addition,
imiquimod had an inhibitory effect on adenylyl cyclase activity downstream from the receptor. Finally, using
transformed human keratinocytes, we provide experimental evidence that imiquimod and A2A adenosine
receptor-specific compounds similarly induce proinflammatory cytokines in the absence of immune cells. Thus,
imiquimod appears to suppress an important feedback mechanism of inflammation by antagonism of
adenosine receptor-dependent increase of cAMP and a concomitant receptor-independent inhibition of cAMP
production. These novel mechanisms presumably act synergistic with the positive induction of proinflamma-
tory cytokines and can, at least in part, explain the profound inflammation observed in some patients in vivo.
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INTRODUCTION
Small molecules with specific activity against malignant or
virally infected cells are attractive candidates with respect to
new antitumoral treatment options. Among such compounds,
immune response modifiers of the imidazoquinoline family,
in particular the lead compound imiquimod, have attracted
considerable interest owing to their profound antiviral and
antitumoral activities (Stanley, 1999; Marks et al., 2001;
Bath-Hextall et al., 2004; Gupta et al., 2004; Scho¨n and
Scho¨n, 2004; Urosevic et al., 2004; Burns and Brown, 2005;
Schulze et al., 2005). Recent studies have demonstrated
elegantly that imidazoquinoline family members exert their
biological activity through direct activation of signaling
through Toll-like receptor (TLR)7 and/or TLR8 (Hemmi
et al., 2002; Jurk et al., 2002; Gorden et al., 2005), both of
which have recently been identified as natural receptors for
single-stranded RNA (Diebold et al., 2004; Heil et al., 2004).
The activity of imiquimod is then mediated, at least in part,
through intracellular activation of the transcription factor
NF-kB, which upon release from its inhibitor IkB migrates to
the nucleus and upregulates transcription of various cytokines
including tumor necrosis factor-alpha (TNFa), IL-2, IL-6,
IL-12, G-CSF, GM-CSF, IFNg, and IFNa, as well as chemokines
such as IL-8, macrophage inflammatory protein-1a, macro-
phage inflammatory protein-1b, and membrane cofactor
protein-1 (Miller et al., 1994; Reiter et al., 1994; Weeks
and Gibson, 1994; Gibson et al., 1995; Megyeri et al., 1995;
Wagner et al., 1997). The net result of these effects is a
profound stimulation of a tumor-directed cellular immune
response that is seen in tumors of different origin, for
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example, cutaneous melanomas and nonmelanoma skin
cancer (Beutner et al., 1999; Marks et al., 2001; Stockfleth
et al., 2001; Bong et al., 2002). Indeed, imiquimod has
demonstrated good efficacy in the topical treatment of basal
cell carcinomas (Beutner et al., 1999; Hannuksela-Svahn
et al., 2000; Marks et al., 2001; Tyring, 2001), cutaneous
squamous cell carcinomas in situ (actinic keratoses and
Bowen’s disease) (Stockfleth et al., 2001; Tyring, 2001), and
cutaneous metastases of malignant melanoma (Steinmann
et al., 2000; Bong et al., 2002; Scho¨n et al., 2004).
Although dendritic cells are thought to be the primary
imiquimod-responsive cell type (Miller et al., 1994; Reiter
et al., 1994; Burns et al., 2000; Suzuki et al., 2000; Hemmi
et al., 2002), imiquimod at higher concentrations also exerts
direct proapoptotic activity against various tumor cell
populations in vitro and in vivo (Scho¨n et al., 2003, 2004;
Sidbury et al., 2003), and it can induce opioid growth factor
receptors in tumor cells (Urosevic et al., 2004).
We report here the surprising observation that the
biological activity of imiquimod is broader and more
complex than could be discerned from previous reports,
inasmuch as the compound induced proinflammatory cyto-
kines in TLR7- and TLR8-negative cells, presumably through
interference with adenosine receptor signaling. Given that
adenosine receptor signaling is involved in inflammatory
cascades (Montesinos et al., 2003; Sitkovsky et al., 2004;
Odashima et al., 2005), there may be an imiquimod-induced
regulatory loop involving adenosine receptors that augments
the inflammatory responses observed in vivo.
RESULTS
Induction of proinflammatory cytokines by the small-molecule
immune response modifier imiquimod in TLR7- and TLR8-
negative cells
To further determine the mode of action of small-molecule
immune response modifiers, we cultured various cell lines,
such as peripheral blood mononuclear cells, keratinocyte-
derived tumor cells, melanoma lines, or leukemia cells, in the
presence of imiquimod and studied their cytokine expression
profile. Most of the transformed cell lines studied did not
express detectable levels of either TLR7 or TLR8 (Figure 1a),
the only imiquimod-binding receptors described thus far
(Hemmi et al., 2002; Jurk et al., 2002; Gorden et al., 2005).
Thus, our results demonstrating that imiquimod induced
upregulation of proinflammatory cytokines including TNFa,
IL-1b, IL-6, and IL-8 in TLR7- and TLR8-negative cells, such
as the keratinocyte-derived cell line HaCaT (Figure 1b, c, and
e), was surprising and indicated a biological activity of
imiquimod that was exerted independent of TLR7, TLR8, or
dendritic cells. Strong induction of both IL-6 and IL-8 mRNA
was observed as early as 30 minutes after exposure of the
cells to imiquimod at 5 mg/ml (1.7- and 56.3-fold, respec-
tively, as determined by densitometric analysis), and the
signal intensity decreased over time (Figure 1b). The TNFa
signal showed a similar, albeit somewhat slower, upregula-
tion (3.8-fold after 1 hour as determined by densitometric
analysis; Figure 1c). On the protein level, we found clear
induction of TNFa, IL-1b, IL-6, and IL-8 in cells incubated
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Figure 1. Imiquimod induces proinflammatory cytokines in TLR7- and TLR8-
negative cells. (a) Expression of TLR7 (upper panel), TLR8 (middle panel), and
GAPDH (loading control, lower panel) was assessed by RT-PCR in freshly
isolated peripheral blood lymphocytes (positive control), the spontaneously
immortalized human keratinocyte line HaCaT, the melanoma lines A375,
Mel-2a, Mel-HO, and MeWo, the T lymphoblast line Jurkat, the erythroleu-
kemia line K562, and HeLa tumor cells. (b) TLR7- and TLR8-negative HaCaT
cells were incubated with imiquimod (5 mg/ml) for the indicated periods of
time, and expression of IL-6 (upper panel), IL-8 (middle panel), and GAPDH
(bottom panel) was assessed by RT-PCR. Both IL-6 and IL-8 are rapidly
upregulated following exposure of the cells to imiquimod. (c) HaCaT cells
were incubated with imiquimod (5 mg/ml) for the indicated time periods, and
expression of TNFa (upper panel) and GAPDH (lower panel) was assessed by
RT-PCR. (d) Activation of the transcription factor NF-kB was assessed in
untreated HaCaT cells (left lane) and HaCaT cells treated with imiquimod
(5 mg/ml for 1 hour) by an electrophoretic mobility shift assay using nuclear
extracts as outlined in Materials and Methods. Please note imiquimod-
induced activation of NF-kB. (e) HaCaT cells were incubated with imiquimod
5mg/ml for 24 hours. Thereafter, cells were fixed, permeabilized, and the
indicated intracellular cytokines were detected as outlined in Materials and
Methods. In each panel, the thin curve represents untreated control cells and
the bold-print curve represents imiquimod-treated cells. Please note that
imiquimod induces expression of TNFa, IL-1b, IL-6, and IL-8 on the protein
level.
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with 5 mg/ml imiquimod as compared to their vehicle-treated
counterparts (increase of mean fluorescence intensities by
25% for TNFa, 52% for IL-1b, 26% for IL-6, and 63% for IL-8;
Figure 1e), whereas only slight or no increase of IFNa,
GM-CSF, or IL-10 was detected (data not shown).
When activation of NF-kB, an important transcription
factor and upstream regulator of many cytokines (including
TNFa, IL-6, and IL-8) (Bonizzi and Karin, 2004), was assessed
in HaCaT cells incubated with imiquimod at concentrations
typically used for TLR-mediated inflammatory responses (i.e.,
5 mg/ml), we found marked activation as detected by
electrophoretic mobility shift assays (Figure 1d).
To formally prove that imiquimod can induce a pro-
inflammatory response in the absence of TLR signaling,
MyD88-deficient mice (Kawai et al., 1999) were studied.
When splenocytes from wild-type mice were incubated in the
presence of 5 or 20 mg/ml imiquimod, a clear upregulation of
IL-1b mRNA was detected (1.77-fold at 5 mg/ml and 2.47-fold
at 20 mg/ml, respectively, as compared to untreated controls).
Interestingly, when splenocytes from MyD88-deficient ani-
mals were assessed, they also showed, albeit at a lower
overall expression level, clear and reproducible upregulation
of IL-1b mRNA (2.09-fold at 5 mg/ml and 2.27-fold at 20 mg/
ml, respectively, as compared to untreated controls; Figure 2,
upper panel). TNFa expression, however, was induced only
in splenocytes from wild-type but not MyD88-deficient mice,
confirming an earlier report (Hemmi et al., 2002) (Figure 2,
middle panel). In any case, these results indicate that
imiquimod exerted some proinflammatory activity in the
absence of TLR/MyD88 signaling.
Binding of imiquimod to adenosine receptors
Based on the aforementioned results, we concluded that
imiquimod, under certain conditions, might act via TLR7-
and TLR8-independent and as yet uncharacterized pathways,
which we sought to identify in the following series of
experiments. Intrigued by the chemical structure of imidazo-
quinoline family members and nucleoside analogs, we tested
the hypothesis that imiquimod interacted with adenosine
receptors.
The binding of imiquimod was tested in radioligand-
binding competition experiments at human A1, A2A, and A3
adenosine receptors in stably transfected Chinese hamster
ovary (CHO) cells. Table 1 summarizes the binding data and
shows that imiquimod binds with micromolar affinity to both
A1 and A2A adenosine receptors (Ki¼2.94 and 2.16 mM,
respectively). The affinity at the A3 subtype was lower as
documented by an approximately 5- to 7-fold higher Ki-value
(Ki¼ 14.6 mM; Table 1). The Ki-values of the analog resiqui-
mod were above 100mM at all three receptor subtypes (data
not shown).
Given that there are currently no suitable radioligands
available for the A2B adenosine receptor, we measured the
effect of imiquimod on adenylyl cyclase activity in stably
transfected CHO cells (Klotz et al., 1998). No agonistic
activity was detected in concentrations as high as 100mM,
whereas weak inhibition of agonist-stimulated adenylyl
cyclase was detected. However, the potency at this receptor
subtype turned out to be too low for a reliable determination
of an IC50-value, which appeared to be approximately 100mM
(data not shown).
Is imiquimod an agonist or an antagonist at adenosine
receptors?
Imiquimod bound to A1, A2A, and A3 adenosine receptors
(Table 1) with an affinity comparable to the methylxanthine
theophylline (Table 1), a prototypical nonselective adenosine
receptor antagonist (Fredholm et al., 2001). In order to detect
a potential agonistic activity, the effect of imiquimod onTNF-
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Figure 2. Imiquimod induces expression of IL-1b mRNA in MyD88-deficient
mice. Splenocytes were isolated from C57BL6 wild-type mice (three left
lanes) or MyD88-deficient C57BL6 animals of the same age (three right lanes).
The cells were incubated for 1 hour with normal medium, 5, or 20 mg/ml
imiquimod as indicated. Expression of IL-1b, TNFa, and GAPDH mRNA was
assessed by RT-PCR as outlined in Materials and Methods.
Table 1. Binding affinities of imiquimod at adenosine
receptor subtypes
Theophylline
Ki-value (nM)
1
Imiquimod
Ki-value (nM) 95% confidence interval n
A1 6,770 2,940 1,870–4,640 6
A2A 1,710 2,160 1,620–2,900 6
A3 86,400 14,600 10,100–21,100 9
1Data from Klotz et al. (1998).
Binding of imiquimod was assessed in radioligand-binding competition
assays using CHO cells stably transfected with the respective human
adenosine receptor subtype and specific radioligands as outlined in
Materials and Methods. Ki-values were determined from at least six
independent experiments with each transfectant cell line. For comparison,
values for the methylxanthine theophylline are given.
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adenylyl cyclase activity was tested in CHO cells stably
transfected with these receptor subtypes. It was found that
imiquimod did not inhibit forskolin-stimulated adenylyl
cyclase activity in CHO cells expressing A1 adenosine
receptors, whereas the A1-selective agonist 2-chloro-N
6-
cyclopentyladenosine (CCPA) caused a 40% inhibition of
the forskolin signal (Figure 3a). Although imiquimod had very
little effect on the forskolin-stimulated adenylyl cyclase
activity, it slightly augmented the inhibition caused by CCPA
(Figure 3a), suggesting an additional receptor-independent
inhibition of adenylyl cyclase. Thus, inhibition of adenylyl
cyclase downstream from the receptor may be responsible for
the failure to demonstrate the antagonistic effect on A1
receptors in the functional experiments.
In CHO cells transfected with A2A adenosine receptors,
imiquimod did not stimulate adenylyl cyclase activity (data
not shown) and, thus, was not an agonist at this receptor
subtype. It inhibited the adenylyl cyclase signal caused by the
agonist CGS 21680 (2-(p-(2-carboxyethyl) phenylethyl-amino)-
adenosine-50-N-ethyluronamide) by about 20% as can be
expected for an antagonist (Figure 3b). However, in these cells
imiquimod also mediated an inhibition of forskolin-stimulated
adenylyl cyclase activity (Figure 3b), again supporting the
notion of a receptor-independent direct or indirect inhibitory
effect on adenylyl cyclase activity.
Although imiquimod exhibited weaker affinity for A3
adenosine receptors, we tested its effect on adenylyl cyclase
in CHO cells expressing this subtype. An approximately 20%
inhibition of forskolin-stimulated adenylyl cyclase was
detected when the cells were incubated with imiquimod,
whereas the agonist N6-(2-chloro-3-iodobenzyl)adenosine-
50-N-methyluronamide resulted in an inhibition by 43%
(Figure 3c). Although this moderate inhibition by imiquimod
is, in principle, consistent with partial agonism, it is more
likely to represent receptor-independent cyclase inhibition
as, in analogy to the results with A1 and A2A receptors,
imiquimod caused an inhibition of forskolin-stimulated
adenylyl cyclase activity.
Given that no agonistic activity of imiquimod was
detected at either of the adenosine receptors, the results
obtained with CHO cells transfected with A1, A2A, and A3
adenosine receptors suggested that imiquimod functioned as
an antagonist at all three receptor subtypes. It also appeared
to be a very weak A2B antagonist (data not shown).
In addition to its activity on adenosine receptors,
imiquimod appeared to exert a receptor-independent effect
on adenylyl cyclase activity, which was further investigated
in wild-type CHO cells, which did not express endogenous
adenosine receptors (Klotz et al., 1998). The results obtained
with these cells indeed confirmed that imiquimod inhibited
cAMP production independent of the presence of adenosine
receptors (Figure 3d).
Adenosine receptor-dependent induction of proinflammatory
mediators as a potential novel mode of action of imiquimod
In order to assess the biological effect(s) of the interaction of
imiquimod with adenosine receptors, two complementary
series of experiments were performed (Figure 4).
As demonstrated by reverse transcriptase-PCR (RT-PCR),
the A2A and A2B receptor sybtypes were expressed by HaCaT
cells, whereas no signals of the A1 and A3 subtypes could be
detected (Figure 4a). Thereafter, in order to assess the
potential functional relevance of adenosine receptors in
HaCaT cells, their presence was studied by radioligand-
binding experiments. Confirming the RT-PCR results, no
specific binding was detectable with the A1-selective high-
affinity agonist [3H]CCPA as well as with the novel A3-
selective agonist [3H]2-hexyn-1-yl-N6-methyladenosine
(based on the recently reported compound 8a in Volpini
et al. (2002)). In contrast, some binding of the A2A-selective
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Figure 3. Imiquimod modulates adenylyl cyclase activity. (a) Activation of
adenylyl cyclase by forskolin (10 mM) in CHO cells stably transfected with the
human A1 receptor was assessed in the presence of the A1-specific agonist
CCPA (1 mM) or imiquimod (100mM) as indicated. Although CCPA markedly
inhibits forskolin-induced adenylyl cyclase activity, imiquimod only has a
marginal effect that does not reach statistical significance. **Po0.01; NS, not
statistically significant. (b) Adenylyl cyclase was activated by the A2A-specific
agonist CGS 21680 (1 mM, second column) or the nonspecific agonist forskolin
(10mM, fourth column) in CHO cells stably transfected with the human A2A
receptor subtype. Imiquimod diminished activation induced by either
compound (columns 3 and 5, respectively). *Po0.05. (c) Activation of
adenylyl cyclase was induced through forskolin in CHO cells stably
transfected with the human A3 receptor subtype (second column). As shown
in columns 3–5, this activity could be diminished by the A3 antagonist
N6-(2-chloro-3-iodobenzyl)adenosine-50-N-methyluronamide (Cl-IB-MECA)
(1 mM) or, to a lesser extent, imiquimod. **Po0.01; *Po0.05; NS, not
statistically significant. (d) Forskolin induced activation of adenylyl cyclase
(second column) in wild-type CHO cells devoid of adenosine receptors
was diminished by imiquimod (third column), suggesting additional
receptor-independent interference with adenylyl cyclase signaling.
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agonist [3H]CGS 21680 and the nonselective agonist
[3H]adenosine-50-N-ethyluronamide could be demonstrated.
As A2A and A2B were expressed by HaCaT cells, but
imiquimod showed no significant A2B-mediated inhibition
of adenylyl cyclase, it was concluded that imiquimod could
only interact with A2A adenosine receptors on HaCaT cells.
It was then established that both activation of NF-kB and
expression of proinflammatory cytokines (i.e., TNFa, IL-6,
and IL-8) were similarly stimulated by imiquimod, TNFa, and
the A2A antagonist, SCH 58261 (5-amino-7-(2-phenylethyl)-
2-(2-furyl)-pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine)
(Figure 4b–d), strongly suggesting that it is a proinflammatory
effect that is mediated by imiquimod in TLR7- and TLR8-
negative cells through adenosine receptor A2A. As assessed
by densitometric analysis of the gels, the signal intensity of
IL-6 mRNA was increased by 71% when imiquimod was
used and 41% when SCH 58261 was used. In case of IL-8,
the respective stimulations were 775 and 300%, respectively.
In the next series of experiments, the proapoptotic activity
of imiquimod (Scho¨n et al., 2003) and specific adenosine
receptor-interacting compounds was assessed. It was found
that only imiquimod exhibited proapoptotic activity, whereas
neither of the adenosine receptor-directed compounds
showed such activity (Figure 4e). In addition, the concentra-
tion of imiquimod used for the induction of cytokines and
activation of the NF-kB complex was 5 mg/ml, that is, a
concentration that was not sufficient to induce apoptosis
(Figure 4e). Finally, co-incubation of the cells with imiqui-
mod and other adenosine receptor-directed compounds did
not abrogate or otherwise alter the proapoptotic activity of
imiquimod. Thus, modulating adenosine receptor signaling
did not detectably affect imiquimod-induced cellular apop-
tosis, at least under the conditions studied here. It appeared,
therefore, that the proapoptotic effect exerted by imiquimod
at higher concentrations (Scho¨n et al., 2003, 2004) was not
dependent on its activity towards adenosine receptors, and
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Figure 4. Similar induction of inflammatory responses, but not apoptosis, by imiquimod and adenosine receptor antagonists. (a) Expression of the adenosine
receptor subtypes A1 (upper panel), A2A (second panel from top), A2 (third panel from top), and A3 (bottom panel) was assessed by RT-PCR in the respective
control cells (i.e., CHO cells stably transfected with the indicated receptor subtype) and HaCaT cells (right lane). Please note that HaCaT cells only express the
A2A and A2B subtypes, but not A1 or A3. (b) HaCaT cells were incubated with imiquimod (5 mg/ml; three left panels) and the A2A-specific antagonist SCH 58261
(three right panels) for the indicated time periods. Expression of IL-6, IL-8, and GAPDH (loading control) was assessed by RT-PCR. Both compounds similarly
induce IL-6 and IL-8. (c) HaCaT cells were treated as outlined in Figure 3b for the indicated time periods. Expression of TNFa and GAPDH (loading control) was
assessed by RT-PCR. Both compounds show similar induction of TNFa. (d) HaCaT cells were cultured in normal medium (left lane) or treated with imiquimod
(5 mg/ml for 1 hour, second lane), the A2A adenosine receptor-specific antagonist SCH 58261 (1 mM; third lane), or TNFa (positive control; fourth lane). Activation
of the transcription factor NF-kB was assessed by an electrophoretic mobility shift assay using nuclear extracts as outlined in Materials and Methods. Imiquimod-
induced activation of NF-kB is similar to that seen with the A2A antagonist or TNFa, which was used as positive control. (e) HaCaT cells were incubated with
imiquimod at concentrations of 5 mg/ml (i.e., 20 mM) or 50 mg/ml (i.e., 200mM), the A1 antagonist DPCPX (8-cyclopentyl-1,3-dipropylxanthine) (1 mM; negative
control), or the A2A antagonist SCH 58261 (1 mM). Thereafter, apoptosis was determined by assessing the generation of histone-bound DNA fragments as
described in Materials and Methods. Please note that concentrations of imiquimod sufficient to induce transcription of proinflammatory cytokines do not induce
apoptosis. In addition, known antagonists of adenosine receptors exert only marginal, if any, apoptotic activity.
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that the adenosine receptor-mediated action was primarily
immune-related.
DISCUSSION
Overall, we have shown that imiquimod binds to adenosine
receptor subtypes with micromolar affinity. It exhibited the
highest affinity for A1 and A2A receptors and 5- to 7-fold
lower affinity for A3 adenosine receptors. Thus, the pharma-
cological profile of imiquimod resembles very much that of
the prototypical adenosine receptor antagonist theophylline
(Klotz et al., 1998). Our data provide the first evidence that
imiquimod is an adenosine receptor antagonist, as no
agonistic activity was detected at all four receptor subtypes.
Our attempts to show antagonism of a respective agonist-
mediated adenylyl cyclase response were hampered by the
finding that imiquimod exerted additional receptor-indepen-
dent direct or indirect inhibition of adenylyl cyclase activity.
This additional activity was clearly shown by inhibition of
forskolin-stimulated adenylyl cyclase activity in CHO cells
expressing no adenosine receptor subtype at all or in cells
transfected with A2A receptors. In addition, a small but highly
reproducible inhibition of basal adenylyl cyclase activity by
imiquimod was observed in all cell lines investigated, again
supporting the concept of an effect of imiquimod on adenylyl
cyclase activity downstream of a G-protein-coupled receptor
modulating cAMP levels.
Based on our results and previously published data regarding
the functions of adenosine receptors, we hypothesize that
imiquimod exerts an as yet unappreciated novel mode of action
resulting in augmented inflammatory responses (schematically
depicted in Figure 4). It has been known for some time that
inflammatory tissue damage is accompanied by the accumula-
tion of extracellular adenosine in inflamed areas owing to its
release into the extracellular space by a variety of cells (Linden,
2001). The activation of A2A receptors induced by extracellular
adenosine leads to the inhibition of inflammatory responses
owing to its ability to induce accumulation of intracellular
cAMP (Sullivan and Linden, 1998). Studies on A2A receptor-
deficient mice provided the first conclusive in vivo evidence that
A2A receptors play a crucial role in the downregulation of acute
inflammation (Ohta and Sitkovsky, 2001; Sitkovsky et al., 2004).
Binding of extracellular adenosine to the A2A receptor leads to
the activation of adenylyl cyclase and to the accumulation of
cAMP, which subsequently results in immunosuppression
(Sullivan and Linden, 1998). Thus, it is conceivable that
antagonistic binding of imiquimod to the A2A receptor results
in decreased activation of adenylyl cyclase. This effect may be
augmented by receptor-independent inhibition of adenylyl
cyclase. The net result would be decreased accumulation of
cAMP and thus diminished immunosuppression (Figure 5).
This novel mode of action of imiquimod described here
may provide an important additional explanation for the
strong imiquimod-induced inflammatory reaction observed
clinically (Beutner et al., 1999), and may also contribute to
the cytokine induction in keratinocytes described earlier
(Kono et al., 1994). It is conceivable that different pathways
result in imiquimod-induced stimulation of cytokine produc-
tion, as the compound induced IL-1b mRNA, but not TNFa
(which is in line with a previous report (Hemmi et al, 2002))
when splenocytes from MyD88-deficient mice were assessed.
Thus, we propose that imiquimod generates inflammation via
at least two complementary and mutually augmenting
mechanisms: on the one hand, it induces the production
of proinflammatory mediators via the known TLR7- and
TLR8-dependent signaling pathways (Hemmi et al., 2002;
Jurk et al., 2002; Gorden et al., 2005). On the other hand,
imiquimod antagonizes an important suppressive feedback
mechanism through A2A adenosine receptor antagonism and
receptor-independent inhibition of adenylyl cyclase activity
even in TLR7- and TLR8-negative cells, thus augmenting the
inflammatory action.
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Figure 5. Synopsis of putative modes of action of imiquimod. The known
mechanisms of imiquimod comprise, on the one hand, TLR7- and TLR8-
mediated activation of the NF-kB signaling cascade and, consecutively,
transcription of proinflammatory cytokines. This effect is observed at low
concentrations of the compound (i.e., approximately 20 mM) and is thought to
be most relevant on dendritic cells. On the other hand, imiquimod exerts
direct death receptor-independent proapoptotic effects on certain cells (e.g.,
tumor cells of different origin) at higher concentrations (i.e., approximately
200mM). Both concentrations are relevant in vivo, as even the higher
concentration is about three logs below the marketed formulation, and
relevant concentrations following topical application have been shown
in vivo. In addition, imiquimod appears to interact with adenosine receptor
signaling pathways at low concentrations even in TLR7- and TLR8-negative
cells. This action presumably results in diminished inhibitory activity of
cAMP on the transcription of proinflammatory mediators. It is, therefore,
conceivable that this novel mechanism impairs an important negative
feedback regulation that normally limits inflammatory responses. The net
result will be an augmentation of inflammatory responses, which may,
at least in part, explain the profound inflammation observed in vivo.
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MATERIALS AND METHODS
Cells and culture conditions
HaCaT (gift from N.E. Fusenig, German Cancer Research Center,
Heidelberg, Germany) is a spontaneously immortalized human
keratinocyte cell line (Boukamp et al., 1988). Peripheral blood
lymphocytes were isolated from human blood by density-gradient
centrifugation as described earlier (Pauls et al., 2001). Mel-2a
(Bruggen et al., 1981), A375 (Giard et al., 1973), Mel-HO
(Holzmann et al., 1988), and MeWo (Bean et al., 1975) are human
melanoma lines. Jurkat, K562, and HeLa cells were from ATCC (LGC
Promochem, Wesel, Germany). The cells were maintained in RPMI
1640 supplemented with 10% fetal calf serum, 2 mM L-glutamine,
100 U/ml penicillin, 100 U/ml streptomycin, and 1% nonessential
amino acids (all from Life Technologies, Karlsruhe, Germany). CHO
cells stably transfected with individual subtypes of the human
adenosine receptors were maintained in DMEM with nutrient
mixture F12 without nucleosides, containing 10% fetal calf serum,
penicillin (100 U/ml), streptomycin (100 U/ml), L-glutamine (2 mM),
and geneticin (G-418, 0.2 mg/ml) at 371C in 5% CO2 as described
earlier (Klotz et al., 1998).
Membrane preparation
Radioligand-binding studies and measurement of adenylyl cyclase
activity was carried out in crude membrane fractions prepared from
fresh or frozen cells according to two slightly different protocols. For
radioligand binding, cells were homogenized and the homogenates
were centrifuged at low speed. Then, membranes were sedimented
in a high-speed centrifugation step followed by resuspension in
binding buffer and storage at 801C. For adenylyl cyclase studies,
membranes were always freshly prepared and the low-speed
centrifugation step was omitted (for details, see Klotz et al., 1998).
Flow cytometry of intracellular proteins (FACS)
To detect intracellular cytokines, trypsinized cells (2 105) were
fixed in 1% paraformaldehyde and permeabilized by incubation in
poration buffer (saponin 0.3%, NaN3 0.1%, fetal calf serum 2% in
phosphate-buffered saline (PBS)) for 5 minutes at 201C. Thereafter,
the cells were incubated with 10 mg/ml of the primary mAb at 41C for
45 minutes, washed twice in PBS, and incubated with R-phyco-
erythrin-conjugated F(ab0)2 fragments of rabbit-anti-mouse Igs (DAKO,
Hamburg, Germany) for 45 minutes at 41C. The cells were then
washed again twice in PBS, and analyzed using a fluorescence-
activated cell analyzer (FACScan from BD Biosciences, Heidelberg,
Germany) and the Cell Quest software (BD Biosciences).
Murine mAbs directed against the following human cytokines
were used: TNFa (IgG1), IL-1b (IgG1), IL-6 (IgG2a), IL-8 (IgG1), IFNa
(IgG1), GM-CSF (IgG1), and IL-10 (IgG1). Isotype-matched murine
IgG was used as negative control (all antibodies from Immunotools,
Friesoythe, Germany).
Radioligand-binding studies
Radioligands were from Perkin-Elmer (Rodgau, Germany). The A2A-
selective antagonist SCH 58261 was kindly provided by P.G. Baraldi
(University of Ferrara, Italy). All other adenosine receptor ligands
were from Sigma (Taufkirchen, Germany). [3H]ZM 241385 and
forskolin were from Tocris/Biotrend (Ko¨ln, Germany). The radio-
ligand-binding experiments were performed according to a pre-
viously described protocol (Klotz et al., 1998, 1999). In brief,
[3H]CCPA (1 nM) was used as a selective radioligand for A1
adenosine receptors, whereas the nonselective radioligand [3H]ade-
nosine-50-N-ethyluronamide (10 nM) was used for A2A and A3
receptors, respectively. Nonspecific binding was determined in the
presence of 1 mM theophylline (A1) or 100mM (R)-N
6-phenylisopro-
pyladenosine (A2A and A3). Ki-values were calculated from
competition curves by nonlinear curve fitting with the program
SCTFIT (De Lean et al., 1982).
Adenylyl cyclase activity
[a-32P]ATP for the determination of adenylyl cyclase activity was
purchased from Perkin-Elmer. The activity of adenylyl cyclase
(duplicates for CGS 21680-treated A2A transfectants, between three
and 10 measurements for other conditions) was assessed to
determine the potential effects of imiquimod (kindly provided by
3M Pharmaceuticals, Neuss, Germany) according to a previously
described protocol (Klotz et al., 1998). Membranes were incu-
bated at 371C in an incubation mixture containing approximately
150 000 c.p.m. of [a-32P]ATP. After 20 minutes, the reaction was
stopped on ice by the addition of ZnAc/Na2CO3. The [
32P]cAMP was
separated during the reaction from [a-32P]ATP by chromatography
using alumina columns and counted in a b-counter (Cerenkov
radiation without scintillator). Statistical significance was assessed
using the Student’s t-test and P-values o0.05 were considered
statistically significant. The basal activities of adenylyl cyclase
(which were used for comparison with the stimulated values) in the
cell lines used were as follows: A1, 23.573.03; A2A, 22.679.06; A3,
22.973.41; and wild type 18.077.04 (all values in pmol/mg
membrane protein/minute7SEM).
Preparation of nuclear extracts and NF-jB electrophoretic
mobility shift assays
Nuclear extracts from untreated cells or cells treated with imiquimod
(5 or 25 mg/ml), SCH 58261 (0.1 or 1 mM), or TNFa (20 ng/ml) were
prepared as described (Aggarwal et al., 2004). Ten micrograms of the
extracts were incubated with 32P-end-labeled, double-stranded NF-
kB oligonucleotide (50-AGT TGA GGG GAC TTT CCC AGG C-30)
(Gel shift assay systems, Promega, Madison, WI) for 20 minutes at
room temperature. Subsequently, the DNA–protein complexes were
resolved in a 6.6% native polyacrylamide gel. The radioactive bands
from the gels were visualized and quantitated using a Phosphor-
Imager and the image quant software.
Semiquantitative RT-PCR
RNA from treated or untreated cells was extracted using the
Rneasy Mini Kit (Quiagen, Hilden, Germany) according to the
manufacturer’s instructions. The expression of adenosine receptor
subtypes A1, A2A, A2B, and A3, as well as TLR7, TLR8, IL-6, IL-8,
TNFa, and GAPDH (control) was assessed by RT-PCR as described
(Hornung et al., 2002; Nguyen et al., 2003). Primers used for
RT-PCR are listed in Table 2. The amplification programs were as
follows: GAPDH – one cycle at 941C for 2 minutes, followed by 26
cycles at 941C for 30 seconds, 631C for 30 seconds, 721C for
40 seconds, and a final cycle at 721C for 5 minutes; adenosine
receptors A1 and A2A as well as TLR7 and TLR8 – one cycle at
941C for 2 minutes, followed by 30 cycles at 941C for 30 seconds,
591C for 30 seconds, 721C for 40 seconds, and a final cycle at
721C for 5 minutes; adenosine receptor subtypes A2B and A3 – one
cycle 941C, 2 minutes; followed by 30 cycles of 941C 30 seconds,
571C 30 seconds, 721C 40 seconds, and a final cycle of 721C for
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5 minutes; TNFa – one cycle at 941C for 2 minutes, followed by 30
cycles at 941C for 30 seconds, 581C for 30 seconds, 721C for
40 seconds, and a final cycle at 721C for 5 minutes; IL-6 and IL-8 –
one cycle at 941C for 2 minutes, followed by 30 cycles at 941C for
30 seconds, 611C for 30 seconds, 721C for 1 minutes, and a final
cycle at 721C for 5 minutes.
Apoptosis detection in vitro (DNA fragmentation assay)
For the detection of cytoplasmic histone-associated DNA fragments,
the Cell Death Detection ELISA was used according to the
manufacturer’s instructions (Roche Diagnostics, Penzberg, Germany).
Briefly, cells were incubated with the distinct proapoptotic stimuli
for 16 hours, harvested (both adherent and detached cells), lyzed
and, by centrifugation at 10,000 g for 10 minutes, a clear super-
natant was prepared. Equal amounts of the supernatant were added
to microtiter plates coated with antihistone antibodies, and incu-
bated for 90 minutes at room temperature. After three washes
with PBS, the secondary antibody (anti-DNA peroxidase antibody)
was added, the samples were incubated for another 90 minutes,
and washed again in PBS. The substrate reaction, resulting in a
green color, was quantitated using an ELISA reader at 405 nm.
All experiments were performed in duplicates, and were repeated at
least three times.
Analysis of MyD88-deficient mice
Whole spleens from MyD88-deficient mice (Kawai et al., 1999)
and wild-type controls on the C57BL6 genetic background were
removed and placed in DMEM cell culture medium. Single-cell
suspensions were prepared by gently teasing the tissue with a sterile
syringe plunger. After hypotonic lysis of erythrocytes, splenocytes
were washed twice with PBS and cultured in 24-well plates in
DMEM supplemented with 10% fetal calf serum, L-glutamine, and
penicillin/streptomycin. From each animal, 3 107 cells were
incubated for 1 hour with 5 mg/ml imiquimod, 20 mg/ml imiquimod,
or were left untreated as a control. Thereafter, the cells were lyzed
and RNA was extracted as described above. Primers used for
detecting murine IL-1b, TNFa, and GAPDH are listed in Table 2.
Conditions for PCR were: one cycle at 941C for 3 minutes followed
by 26 cycles each of 941C for 30 seconds, 561C for 30 seconds, 721C
for 45 seconds, and a final cycle of 721C for 10 minutes. Animal
experiments were approved by the respective authorities.
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Table 2. Primer sequences used in RT-PCR
Name Type Sequence bp
hGAPDH Forward 50-TGAAGGTCGGAGTCAACGGATTTGGT-30 983
Reverse 50-CATGTGGGCCATGAGGTCCACCAC-30
hIL-6 Forward 50-ATGAACTCCTTCTCCACAAGCGC-30 628
Reverse 50- GAAGAGCCCTCAGGCTGGACTG-30
hIL-8 Forward 50-ACGAATTCCTAGGACAAGAGCCAGGAAG-30 253
Reverse 50-GTGAATTCAGTGTGGTCCACTCTCAATC-30
hTNFa Forward 50-GAAAGCATGATCCGGGACGT-30 489
Reverse 50-CTTGGTCTGGTAGGAGACGG-30
hTLR7 Forward 50-GGGCCCATCTCAAGCTGATC-30 345
Reverse 50-TGTGAAAGGACGCTGGGGAG-30
hTLR8 Forward 50-TGCGCTGCTGCAAGTTACGG-30 413
Reverse 50-GTTGAGGAATGCCCCGTCTG-30
hAR-A1 Forward 5
0-TCCATCTCAGCTTTCCAGGC-30 515
Reverse 50-CTCGAACTCGCACTTGATCAC-30
hAR-A2A Forward 5
0-ACCTGCAGAACGTCACCAAC-30 524
Reverse 50-CACAGGACGCGCTGTACGTG-30
hAR-A2B Forward 5
0-CACAGGACGCGCTGTACGTG-30 464
Reverse 50-TTCTGTGCAGTTGTTGGTGG-30
hAR-A3 Forward 5
0-AACGTGCTGGTCATCTGCGTGGTC-30 440
Reverse 50-GTAGTCCATTCTCATGACGGAAAC-30
mIL-1b Forward 50-CTGGTGTGTGACGTTCCCATTA-30 209
Reverse 50-TTCTTTCCTTTGAGGCCCAAGG-30
mTNFa Forward 50-GCCTCTTCTCATTCCTGCTT-30 202
Reverse 50-ACTTGGTGGTTTGCTACGAC-30
mGAPDH Forward 50-TGGCAAAGTGGAGATTGTTG-30 224
Reverse 50-GTATGTCGTGGAGTCTACTG-30
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